Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 3/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 3/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 6/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101254 | 0.80 | CYP3A4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4MAPT | |
| SCHEMBL7101251 | 0.80 | CYP3A4 (0.43) | CHRNB4CHRNA3CHRNB2CHRNA4MAPT | |
| SCHEMBL1292952 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL1711411 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL4873027 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL16105229 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL2760982 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL2760561 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL1292916 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 | |
| SCHEMBL2114569 | 0.76 | CHRNB4 (0.48) | CHRNB4CHRNA3CHRNB2CHRNA4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344476-B1 | TRICYCLIC CARBAMATE JAK INHIBITORS | RIGEL PHARMACEUTICALS INC (US) | 2015-04-29 | — | — | EP | disclosed |
| US-20140363443-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-20140363443-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-11 | — | — | US | disclosed |
| US-8846908-B2 | Tricyclic carbamate JAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8846908-B2 | Tricyclic carbamate JAK inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-20110269749-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140363443-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | JAK3, JAK2, JAK1 | CHRNB4 4756/4885CHRNA3 3547/4885CHRNB2 4780/4885 |
| US-20110269749-A1 | TRICYCLIC CARBAMATE JAK INHIBITORS | JAK3, JAK2, JAK1 | CHRNB4 4756/4885CHRNA3 3547/4885CHRNB2 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.